Stock News•1 months ago
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
Eli Lilly's Olumiant received FDA approval to treat severe alopecia areata in patients 12 and older, expanding its U.S. label after strong phase III results.
MarketLens
What Does Olumiant's EU Recommendation Mean for Eli Lilly
8 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•1 months ago
Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything
Eli Lilly's core therapeutic breakthroughs are driving strong financial results, but clinical setbacks could create significant headwinds if innovation stalls.
Stock News•1 months ago
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
Eli Lilly's immunology portfolio is gaining ground with steady revenue growth, pipeline expansion, and acquisitions, broadening its next wave of growth beyond GLP-1s.
Breaking News
View All →Featured Articles
Top Headlines
Stock News•59 minutes ago
Jim Cramer sees major implications from SK Hynix's home-run quarter
Stock News•1 hour ago
Google parent Alphabet tumbles after profit disappoints, warns AI is battering its cash flow
Stock News•1 hour ago
Jim Cramer says these tech giants can weather market turbulence
Stock News•1 hour ago
Alphabet Inc. (GOOG) Misses Q3 Earnings and Revenue Estimates
Stock News•1 hour ago